MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Rhea-AI Summary

MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its fourth quarter and year-end 2023 financial results on March 21, 2024. The company focuses on developing iNKT cell therapies for cancer and immune-mediated diseases.

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year-end 2023 financial results before the market opens on Thursday, March 21, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

Conference Call

Dial-in numbers: 646-307-1963 (U.S. – NY), 800-715-9871 (U.S. & Canada)

Conference ID: 1391457

Webcast

A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/xa2m5uy7.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Investor Contact

917-362-1370

investor@minktherapeutics.com

Media Contact

781-674-4428

communications@minktherapeutics.com

FAQ

When will MiNK Therapeutics, Inc. release its fourth quarter and year-end 2023 financial results?

MiNK Therapeutics, Inc. will release its fourth quarter and year-end 2023 financial results before the market opens on Thursday, March 21, 2024.

What is the focus of MiNK Therapeutics, Inc.?

MiNK Therapeutics, Inc. focuses on pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.

When will the conference call and webcast regarding the financial results take place?

MiNK executives will host a conference call and webcast at 8:30 a.m. ET on Thursday, March 21, 2024, to discuss the results and provide a corporate update.